Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Go back to Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors| TORREYPINES THERA (NASDAQ: TPTX) | Delayed: 76.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $76.01 | 52 Week High | $0.69 | |||
| Open | $76.01 | 52 Week Low | $0.07 | |||
| Day High | $76.01 | P/E | N/A | |||
| Day Low | $76.01 | EPS | $-0.90 | |||
| Volume | 26,350 | |||||
